PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein

製品番号/仕様
価格
Availability
数量
HL1-HP2E5-25tests
$620.00
In Stock - Delivery in 2-3 business days
HL1-HP2E5-200tests
$3,710.00
In Stock - Delivery in 2-3 business days
HL1-HP2E5
製品金額 :
$ 0
推奨新製品 Request Quote
Contact Us
Contact Us
製品金額:
$ 0
  • 製品詳細
  • データ表示
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

HLA-A*0201 & B2M & NY-ESO-1 (SLLMWITQC)

Source

PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein (HL1-HP2E5) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & SLLMWITQC peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769-1 (B2M) & SLLMWITQC).

Predicted N-terminus: Gly 25 & Ser

Molecular Characterization

PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein is assembled by biotinylated monomer (HL1-H82E6) and PE-labeled streptavidin.

Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein is produced by co-expression of HLA and B2M loaded with NY-ESO-1 peptide. Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

Conjugate

PE

Excitation Wavelength: 488 nm / 561 nm

Emission Wavelength: 575 nm

Formulation

Lyophilized from 0.22 μm filtered solution in 0.2% BSA with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please protect from light and avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.

バックグランド

NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. The Human HLA-A*0201 NY-ESO-1 complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M and SLLMWITQV peptide of the NY-ESO-1.